Impact of changes to reimbursement of fixed combinations of inhaled corticosteroids and long-acting β₂ -agonists in obstructive lung diseases: a population-based, observational study - Wikidata - awgldk - TriplyDB

Impact of changes to reimbursement of fixed combinations of inhaled corticosteroids and long-acting β₂ -agonists in obstructive lung diseases: a population-based, observational study

Impact of changes to reimbursement of fixed combinations of inhaled corticosteroids and long-acting β₂ -agonists in obstructive lung diseases: a population-based, observational study

http://www.wikidata.org/entity/Q35022943

about

Is higher population-level use of ICS/LABA combination associated with better asthma outcomes? Cross-sectional surveys of nationally representative populations in New Zealand and Australia.Budesonide inhaler device switch patterns in an asthma population in Swedish clinical practice (ASSURE).

P2860

Q38632713-E63A258F-B211-4FB5-BF94-D542A3D99037 Q40669163-238B9258-57E8-43B4-BDFB-69AE0E6A0C3F

P2860

Impact of changes to reimbursement of fixed combinations of inhaled corticosteroids and long-acting β₂ -agonists in obstructive lung diseases: a population-based, observational study

http://www.wikidata.org/entity/Q35022943

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Impact of changes to reimburse ...... ion-based, observational study

@ast

Impact of changes to reimburse ...... ion-based, observational study

@en

type

label

Impact of changes to reimburse ...... ion-based, observational study

@ast

Impact of changes to reimburse ...... ion-based, observational study

@en

prefLabel

Impact of changes to reimburse ...... ion-based, observational study

@ast

Impact of changes to reimburse ...... ion-based, observational study

@en

P1433

Q35022943-06621BD9-9DA6-4B3D-90B5-1AD47B0DE485

P1476

Q35022943-4B71D657-283C-4059-8C2E-1A622FFEC756

P2093

Q35022943-3E38B88A-4891-44D9-A9FD-0975870F7256

Q35022943-75DE921D-7AA3-4665-9301-DA39629AE88B

Q35022943-88910CE1-E830-480C-AB5B-DE4120357487

Q35022943-9F2E02FC-6D20-4FC9-8CA0-F81A8B9051FE

Q35022943-D9740B05-DF74-4824-9160-1736412F1388

Q35022943-EC601E5D-EC38-4628-93E8-440B625C9D6E

P2860

Q35022943-165384AD-A8E0-4340-A093-F25F239B365C

Q35022943-173E8E9F-499E-4A35-8ECA-EB5C2A7FA9C3

Q35022943-1E145DAF-1F57-4CCC-8135-8EC06B997E6F

Q35022943-1E29FE1D-221C-4550-A97F-D7027083B2A8

Q35022943-23A384FA-E69D-4415-B670-19A831C34AEC

Q35022943-2593B893-EAA9-4856-A289-52CD1E56307D

Q35022943-4EE1B8D3-FE11-4D8E-BCA4-42694323EE67

Q35022943-51C71487-3F2A-4EE1-AD31-5B3E055A502F

Q35022943-5C468CBF-AC01-442A-9210-EF1E2E5B6CEE

Q35022943-7468019B-F03F-4037-90D0-BC70BA2948CE

P304

Q35022943-9CA30EB4-2C5C-4DB0-BA86-D7240D330A87

P31

Q35022943-9B3766D9-7FE9-4C6C-A2C3-218FDF3AA657

P356

Q35022943-C6F8B048-6AEB-4577-B7BE-FA427F5DB4C7

P433

Q35022943-E2C1B86C-7AA2-4C80-96EA-4AC4A6ED21E5

P478

Q35022943-9638BBFA-2A43-4DB7-ABEE-0659B354EB0A

P50

Q35022943-36E0C6D4-AF30-4ECA-96C0-CFB414C23844

Q35022943-5CBC6AB1-A5D6-4A41-9FBB-DC00AD81AA12

P577

Q35022943-FF57AD37-CF79-487E-A4B9-F3645FF98E19

P5875

Q35022943-E0001B6E-A672-45A6-867E-E8662BD66CC2

P698

Q35022943-BC110F34-D0A5-4757-A79F-D115491B5681

P932

Q35022943-F94FC077-C2EC-4262-9AF6-7950E4D85414

P356

P1433

International Journal of Clinical Practice

P1476

Impact of changes to reimburse ...... ion-based, observational study

@en

P2093

G Telg

http://www.w3.org/2001/XMLSchema#string

I Naya

http://www.w3.org/2001/XMLSchema#string

J S Jonsson

http://www.w3.org/2001/XMLSchema#string

M Jonsson

http://www.w3.org/2001/XMLSchema#string

S T Sigurðardóttir

http://www.w3.org/2001/XMLSchema#string

U S Björnsdóttir

http://www.w3.org/2001/XMLSchema#string

P2860

Loss of asthma control in pediatric patients after discontinuation of long-acting Beta-agonists

Quality of care for older adults with chronic obstructive pulmonary disease and asthma based on comparisons to practice guidelines and smoking status

Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control.

Pharmaceutical policies in European countries in response to the global financial crisis.

Reassessing the evidence hierarchy in asthma: evaluating comparative effectiveness.

Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma.

Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial.

Out-of-pocket medication costs and use of medications and health care services among children with asthma.

Long-acting β2-agonist step-off in patients with controlled asthma.

Potential negative consequences of non-consented switch of inhaled medications and devices in asthma patients.

P304

812-819

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IJCP.12473

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P50

Sveinbjorn Gizurarson

Marcus Thuresson

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263294226

http://www.w3.org/2001/XMLSchema#string

P698

24942308

http://www.w3.org/2001/XMLSchema#string

P932

4309409

http://www.w3.org/2001/XMLSchema#string